nifedipine has been researched along with probucol in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Achmad, TH; Rao, GS | 1 |
| Black, CM; Bruckdorfer, KR; Bunce, TD; Denton, CP; Dorado, MB; Howell, K; Roberts, Z; Wilson, H | 1 |
| Camargo, F; Erickson, RP; Garver, WS; Heidenreich, RA; Hossain, GS | 1 |
| Horiai, H; Ohtsuka, M; Oyanagui, Y | 1 |
| Blanchard, J; Camargo, F; Carbone, PN; Erickson, RP; Garver, WS; Heidenreich, RA; Hossain, GS | 1 |
1 trial(s) available for nifedipine and probucol
| Article | Year |
|---|---|
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.
Topics: Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Cohort Studies; Humans; Lipoproteins; Lipoproteins, LDL; Nifedipine; Oxidation-Reduction; Probucol; Raynaud Disease; Scleroderma, Systemic; Triglycerides; Vasodilator Agents; Vitamin E | 1999 |
12 other study(ies) available for nifedipine and probucol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers.
Topics: Aspirin; Calcium Channel Blockers; Chemotaxis, Leukocyte; Diltiazem; Dose-Response Relationship, Drug; Endothelins; Humans; In Vitro Techniques; Indomethacin; Kinetics; Monocytes; Neomycin; Nifedipine; Probucol; Thioctic Acid; Verapamil | 1992 |
Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice.
Topics: Animals; Blood-Brain Barrier; Cholesterol; Mice; Mice, Inbred BALB C; Mice, Knockout; Niemann-Pick Diseases; Nifedipine; Probucol; Receptors, LDL | 2000 |
Effect of nilvadipine in weak acidic medium by 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay.
Topics: Amlodipine; Anticholesteremic Agents; Antioxidants; Bepridil; beta Carotene; Biphenyl Compounds; Buffers; Calcium Channel Blockers; Free Radicals; Hydrogen-Ion Concentration; Nifedipine; Picrates; Probucol | 2001 |
Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Anticholesteremic Agents; Ataxia; beta-Cyclodextrins; Blood-Brain Barrier; Brain; Cholesterol; Cyclodextrins; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Injections, Spinal; Intracellular Signaling Peptides and Proteins; Liver; Male; Mice; Mice, Knockout; Niemann-Pick C1 Protein; Niemann-Pick Diseases; Nifedipine; Probucol; Proteins; Tremor | 2001 |